2,217 Shares in Gilead Sciences, Inc. $GILD Bought by Sax Wealth Advisors LLC

Key Points

• Sax Wealth Advisors LLC invested approximately $248,000 in Gilead Sciences, purchasing 2,217 shares in the first quarter.
• Recent ratings from analysts include upgrades from Truist Financial and Daiwa Capital Markets, with target prices raised to between $127.00 and $128.00.
• Gilead Sciences announced a quarterly dividend of $0.79 per share, representing an annualized yield of 2.8%, payable on September 29th.

Sax Wealth Advisors LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,217 shares of the biopharmaceutical company's stock, valued at approximately $248,000.

A number of other large investors also recently modified their holdings of GILD. Brighton Jones LLC lifted its position in shares of Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Integrated Wealth Concepts LLC raised its stake in shares of Gilead Sciences by 4.7% during the fourth quarter. Integrated Wealth Concepts LLC now owns 26,687 shares of the biopharmaceutical company's stock worth $2,465,000 after buying an additional 1,194 shares during the last quarter. Nebula Research & Development LLC bought a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $288,000. Two Sigma Securities LLC raised its stake in shares of Gilead Sciences by 164.4% during the fourth quarter. Two Sigma Securities LLC now owns 2,253 shares of the biopharmaceutical company's stock worth $208,000 after buying an additional 5,753 shares during the last quarter. Finally, Capital Analysts LLC raised its stake in shares of Gilead Sciences by 8.5% during the fourth quarter. Capital Analysts LLC now owns 5,444 shares of the biopharmaceutical company's stock worth $503,000 after buying an additional 426 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares in the company, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the completion of the transaction, the chief financial officer owned 160,110 shares of the company's stock, valued at $18,977,838.30. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $9,339,230 over the last ninety days. 0.27% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on GILD. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a research note on Tuesday, August 19th. Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. UBS Group boosted their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Finally, Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Stock Down 1.2%

Shares of Gilead Sciences stock traded down $1.36 on Thursday, hitting $112.56. The company had a trading volume of 4,145,892 shares, compared to its average volume of 8,193,325. The firm has a market capitalization of $139.67 billion, a P/E ratio of 22.42, a P/E/G ratio of 0.70 and a beta of 0.33. Gilead Sciences, Inc. has a twelve month low of $77.74 and a twelve month high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The stock has a 50-day moving average of $112.83 and a 200-day moving average of $109.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio is 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.